Skip to main content
main-content

The independent medical news service

Lung cancer

03-07-2020 | Oncology | News | Article

Potential for anticancer, COVID-19 drug interactions highlighted

A French team has drawn attention to the potential for drug–drug interactions between anticancer medications and agents being used or tested for the treatment of COVID-19.

02-07-2020 | Oncology | News | Article

Support for ‘plasma-first’ approach in molecular testing for NSCLC

Comprehensive circulating tumor DNA analysis can identify therapeutically targetable driver and resistance mutations in patients with advanced non-small-cell lung cancer, research indicates.

29-06-2020 | Oncology | News | Article

Entrectinib receives positive decision from EMA

More details about the announcement are a click away

26-06-2020 | Oncology | News | Article

First-line stereotactic radiosurgery an option for brain metastases in SCLC

Patients with small-cell lung cancer and brain metastases may benefit from first-line treatment with stereotactic radiosurgery, suggest findings from the FIRE-SCLC study.

26-06-2020 | Oncology | News | Article

Lung cancer patient-specific factors ‘greatest determinants’ of COVID-19 severity

The burden of severe COVID-19 tends to be high in people with lung cancer, with patient-specific factors having the greatest impact on severity, indicates a chart review from a single center.

25-06-2020 | Oncology | News | Article

On-target TRK inhibitor safety profile highlighted

TRK inhibitor therapy has a “unique” profile of adverse events, suggests a review of lung cancer and other oncology patients attending the Memorial Sloan Kettering Cancer Center in New York, USA.

23-06-2020 | Oncology | News | Article

First-line pembrolizumab–chemotherapy prolongs PFS in extensive-stage SCLC

Patients with extensive-stage small-cell lung cancer derive a progression-free survival benefit from first-line treatment with pembrolizumab plus chemotherapy, show phase 3 KEYNOTE-604 trial findings.

22-06-2020 | Oncology | News | Article

Low-dose erlotinib ‘a valid treatment option’ for older, frail NSCLC patients

A phase 2 trial suggests that low-dose erlotinib has clinical activity and a favorable safety profile among older and frail non-small-cell lung cancer patients with EGFR activating mutations.

17-06-2020 | Oncology | News | Article

Lurbinectedin approved for US metastatic SCLC patients

Click through to read more

15-06-2020 | Oncology | News | Article

Brigatinib indication expanded in USA

Click through for more information about this FDA decision

09-06-2020 | Oncology | News | Article

Pembrolizumab and concurrent chemoradiotherapy show unresectable stage III NSCLC promise

For patients with unresectable stage III non-small-cell lung cancer, first-line pembrolizumab plus concurrent chemoradiotherapy is feasible, say the KEYNOTE-799 investigators.

08-06-2020 | Oncology | News | Article

VISION: Tepotinib promising for MET exon 14-mutated advanced NSCLC

Individuals with advanced non-small-cell lung cancer positive for MET exon 14 skipping mutations could benefit from treatment with the selective MET inhibitor tepotinib, suggests a phase 2 trial.

05-06-2020 | Oncology | News | Article

Concurrent osimertinib–gefitinib feasible in advanced EGFR-mutated NSCLC

Combining osimertinib with gefitinib has promising efficacy and tolerability in treatment-naïve patients with metastatic EGFR-mutated non-small-cell lung cancer, suggest early data presented at the virtual 2020 ASCO Annual Meeting.

02-06-2020 | Oncology | News | Article

CheckMate 9LA points to first-line nivolumab–ipilimumab plus chemo for advanced NSCLC

CheckMate 9LA findings reported at the virtual 2020 ASCO Annual Meeting support the use of nivolumab plus ipilimumab alongside first-line, histology-driven chemotherapy in advanced non-small-cell lung cancer patients without sensitizing EGFR or ALK mutations.

30-05-2020 | Oncology | News | Article

Adjuvant osimertinib ‘practice changing’ for early-stage EGFR-mutated NSCLC

Patients with stage IB–IIIA non-small-cell lung cancer harboring EGFR mutations derive a significant disease-free survival benefit from adjuvant treatment with osimertinib, shows the phase 3 ADAURA trial.

15-05-2020 | Oncology | News | Article

Selpercatinib receives FDA nod

Read more about this approval here

15-05-2020 | Oncology | News | Article

PD-1 blockade may not adversely affect COVID-19 outcomes

Treatment with PD-1 inhibitors does not appear to worsen the severity of SARS-CoV-2 infection in patients with lung cancer, suggests a single-center analysis.

07-05-2020 | Oncology | News | Article

FDA approves capmatinib for MET exon 14-mutated NSCLC

Click through for the details

06-05-2020 | Oncology | News | Article

Tumor infiltrating lymphocyte therapy feasible for metastatic NSCLC

Patients with metastatic non-small-cell lung cancer may respond to adoptive cell therapy using tumor infiltrating lymphocytes, suggest results from a small phase 1 trial.

04-05-2020 | Oncology | News | Article

ZENITH20 data suggest poziotinib potential for NSCLC with EGFR exon 20 insertions

The selective EGFR–tyrosine kinase inhibitor poziotinib has clinical activity in previously treated non-small-cell lung cancer patients harboring EGFR exon 20 insertions, suggest phase 2 study data presented at the 2020 AACR Virtual Annual Meeting I.

Image Credits